CompletedNot Applicable

Picosecond Laser for Ttreatment of Benign Pigmented Lesions

United States, China60 participantsStarted 2013-12

Plain-language summary

The purpose of this study is to determine whether Pico laser is effective and safe in the treatment of benign pigmented lesions.

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Has Fitzpatrick skin type I-VI
✓. Has unwanted benign pigmented lesions including but not limited to solar lentigines, freckles, café au lait, melasma, New of Ota, Nevus of Ito, and hyperpigmentation, and wishes to undergo laser treatments to remove them
✓. Is willing to sign an informed consent form to participate in the study
✓. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits

✕. Is hypersensitive to light exposure
✕. Has an active sun tan
✕. Has active localized or systemic infection
✕. Is taking medication(s) for which sunlight is a contraindication
✕. Has a history of squamous cell carcinoma or melanoma
✕. Has a history of keloid scarring
✕. Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment, e.g., lack of noticeable skin flaking, skin peeling and skin surface roughness.
✕. Has had a laser procedure, a peel or has used lightening creams in the area to be treated with in the past six months

Global percentage of pigment clearance

Timeframe: 3 months post the final treatment

NCT IDNCT02146820

SponsorSyneron Medical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-05

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Has Fitzpatrick skin type I-VI
✓. Has unwanted benign pigmented lesions including but not limited to solar lentigines, freckles, café au lait, melasma, New of Ota, Nevus of Ito, and hyperpigmentation, and wishes to undergo laser treatments to remove them
✓. Is willing to sign an informed consent form to participate in the study
✓. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits

✕. Is hypersensitive to light exposure
✕. Has an active sun tan
✕. Has active localized or systemic infection
✕. Is taking medication(s) for which sunlight is a contraindication
✕. Has a history of squamous cell carcinoma or melanoma
✕. Has a history of keloid scarring
✕. Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment, e.g., lack of noticeable skin flaking, skin peeling and skin surface roughness.
✕. Has had a laser procedure, a peel or has used lightening creams in the area to be treated with in the past six months